Managing Director at SCITARI – The CV Tribune

Due diligence on a biosequence assets portfolio

Christian Velten — Sat, 29 May 2004 09:50:00 +0000

Between 2000 and 2008, I investigated prior art, freedom-to-operate, infringement evidences and patent portfolios for reputable patent attorneys and life science industry clients, like Roche and BASF. In 2004, I ad-hoc joined a BASF due diligence team that was preparing a company buy-in as an external expert for analyzing the biosequences portfolio (assets) of the company planned to [...]

Source

Market monitoring for Sanofi Pasteur

Christian Velten — Fri, 25 Apr 2003 09:50:00 +0000

Following a customized market analysis, I provided Sanofi Pasteur with an online platform for continuous market monitoring. Originally Sanofi representatives asked for regular print updates of the successfully provided market analysis. I took the initiative offering a permanently updated, password-protected online portal directly giving access to all data as well as latest findings. Together with my [...]

Source

BIONEWS/Inside-Lifescience eZine published

Christian Velten — Fri, 07 Apr 2000 15:42:00 +0000

In the early 2000’s, I designed and realized one of the first German online magazines on Life Science business on behalf of GIT Publishing Ltd.. Concept and implementation included a multi-channel publishing approach. That was publishing the same content on a website (eZine), via an email-newsletter, and as WAP edition for PDAs and mobile phones (at those pre-smartphone, pre-Android [...]

Source

Business start-up SCITARI successfully established

Christian Velten — Fri, 01 Jan 1999 16:44:00 +0000

Obviously, one of my most exciting projects had been establishing my own business, SCITARI – Dr. Christian Velten Informationsdienste, in 1999. Together with my team I supported life science industries with information research & analysis, digital media and market/competitor intelligence. Starting from scratch, I successively developed business with major life science market players (Roche, Aventis/Sanofi, BASF, Bayer), reputable [...]

Source